<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366236</url>
  </required_header>
  <id_info>
    <org_study_id>RM01-3017</org_study_id>
    <nct_id>NCT00366236</nct_id>
  </id_info>
  <brief_title>Study of Nitazoxanide in the Treatment of Amebiasis in Adults and Adolescents</brief_title>
  <official_title>Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Romark Laboratories L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Romark Laboratories L.C.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of nitazoxanide tablets in treating&#xD;
      diarrhea caused by Entamoeba histolytica in adults and adolescents.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date>November 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of clinical symptoms of amebiasis</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eradication of cyst or trophozoites of E. histolytica from post-treatment stool samples</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from initiation of treatment to passage of last unformed stool</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Amebiasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥12 years.&#xD;
&#xD;
          -  Patients with diarrhea (≥3 bowel movements/day) with one or more enteric symptoms such&#xD;
             as bloody stools, rectal bleeding or enlarged colon.&#xD;
&#xD;
          -  Positive stool ELISA test for Entamoeba histolytica within 7 days prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with identified causes of diarrhea other than E. histolytica.&#xD;
&#xD;
          -  Use within 2 weeks of enrollment of any drug or therapy with possible anti-protozoal&#xD;
             activity.&#xD;
&#xD;
          -  Females who are pregnant, suspected of being pregnant or breastfeeding.&#xD;
&#xD;
          -  Serious systemic disorders incompatible with the study.&#xD;
&#xD;
          -  History of hypersensitivity to nitazoxanide.&#xD;
&#xD;
          -  Patients in whom the possibility of receiving placebo and not being able to receive&#xD;
             immediately an effective treatment will be incompatible with the severity of the&#xD;
             patient's illness.&#xD;
&#xD;
          -  Patients with amebic liver abscess.&#xD;
&#xD;
          -  Patients known to have or suspected of having AIDS.&#xD;
&#xD;
          -  Patient with immune deficiencies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir M Kabil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benha University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yehia El-Gohary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benha University Hospital</name>
      <address>
        <city>Benha</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>August 18, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2006</study_first_posted>
  <last_update_submitted>August 18, 2006</last_update_submitted>
  <last_update_submitted_qc>August 18, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2006</last_update_posted>
  <keyword>Amebiasis</keyword>
  <keyword>Entamoeba histolytica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amebiasis</mesh_term>
    <mesh_term>Dysentery, Amebic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

